Logo

Illumina: Jay Flatley, John Thompson

Mar 18, 2021

Illumina announced that Jay Flatley will step down from the company's board of directors and John Thompson will replace him as chairman of the board, effective May 26.

"This is part of a thoughtful, long-term succession planning process," Illumina said in a statement.

Flatley led Illumina as CEO from 1999 to 2016 and served as executive chair from 2016 to 2019. He spearheaded Illumina's acquisition of Solexa and with it the underlying technology for Illumina's next-generation sequencing systems.

Thompson has served on Illumina's board since 2017. He is a venture partner at Lightspeed Ventures. Previously, he was CEO at Virtual Instruments and Symantec and held senior roles in sales, marketing, and software development in a 28-year career at IBM. Thompson is also chair of Microsoft's board, a position he has held since 2014, and serves on the boards of privately-held Rubrik and Seismic Software. He holds a master's degree in management science from the Massachusetts Institute of Technology's Sloan School of Management.

Breaking News
The Scan

Genetic Testing Approach Explores Origins of Blastocyst Aneuploidy

Investigators in AJHG distinguish between aneuploidy events related to meiotic missegregation in haploid cells and those involving post-zygotic mitotic errors and mosaicism.

Study Looks at Parent Uncertainties After Children's Severe Combined Immunodeficiency Diagnoses

A qualitative study in EJHG looks at personal, practical, scientific, and existential uncertainties in parents as their children go through SCID diagnoses, treatment, and post-treatment stages.

Antimicrobial Resistance Study Highlights Key Protein Domains

By screening diverse versions of an outer membrane porin protein in Vibrio cholerae, researchers in PLOS Genetics flagged protein domain regions influencing antimicrobial resistance.

Latent HIV Found in White Blood Cells of Individuals on Long-Term Treatments

Researchers in Nature Microbiology find HIV genetic material in monocyte white blood cells and in macrophages that differentiated from them in individuals on HIV-suppressive treatment.